AG
RGLS

Aperio Group’s Regulus Therapeutics RGLS Stock Holding History

Aperio Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-95
Closed -$33K – 2079
2016
Q2 		$33K Sell
95
-1
-1% -$716 ﹤0.01% 1995
2016
Q1 		$80K Buy
+96
New +$76.4K ﹤0.01% 1987

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aperio Group's RGLS Position: Q3 2016 in Review

Aperio Group sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 95 shares — an estimated $33K sold.

Aperio Group first reported a position in RGLS in Q1 2016 and held it in 2 quarters. The position peaked at $80K in Q1 2016. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

  • Aperio Group reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Aperio Group sold 95 Regulus Therapeutics shares in Q3 2016, an estimated $33K.
  • Aperio Group first reported a position in Regulus Therapeutics in Q1 2016 and held it in 2 quarters.
  • Aperio Group's Regulus Therapeutics position peaked at $80K in Q1 2016.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Aperio Group's 13F filing for Q3 2016, filed 2 Nov 2016.